Clinical trials: Hemophilia A
Severe Haemophilia
Occupational Integration of Adults With Severe Haemophilia in France: a Study Based on the FranceCoag Cohort
Severe haemophilia and subsequent arthropathy result in joint pain, disability and impaired health-related quality of life. Improvements in haemophilia care over the last decades might lead to expectation of a near-normal quality…
- Trial name
- INTHEMO (NCT03301376)
- Where
- France
- Volunteers
- 590 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Congenital Bleeding Disorder, Haemophilia A
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
This trial is conducted globally. The aim of this trial is to investigate safety, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of concizumab…
- Trial name
- NCT02490787
- Testing
- Concizumab
- Where
- 34 sites in United States, Australia and 13 more
- Volunteers
- 24 people
- Sponsor
- Novo Nordisk A/S
Hemophilia
Manual Therapy in the Treatment of Hemophilic Arthropathy of the Ankle
Introduction: Hemophilic ankle arthropathy is manifested by degenerative functional alterations (deficit of muscle strength, mobility and proprioception), intra-articular alterations and chronic pain.
- Trial name
- NCT05549843
- Testing
- Manual therapy
- Where
- Spain
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Investigación en Hemofilia y Fisioterapia
Congenital Bleeding Disorder, Haemophilia A With Inhibitors
Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice
This study is conducted in Japan. The aim of this non-interventional study is to investigate the safety and effectiveness of treatment with eptacog alpha (NovoSeven®) under normal clinical practice conditions.
- Conditions
- Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
- Trial name
- NCT01579955
- Testing
- eptacog alfa (activated)
- Where
- Japan
- Volunteers
- 321 people
- Sponsor
- Novo Nordisk A/S
Hemophilia A, Hemophilia B
An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia
This pilot project was developed to investigate subjective and objective data related to the patterns of physical activity participation among hemophilia patients (FVIII or FIX) between the ages of 5 and 18 years.
- Conditions
- Hemophilia A, Hemophilia B, Factor VIII Deficiency, Factor IX Deficiency
- Trial name
- HEPS (NCT02199717)
- Testing
- Accelerometer
- Where
- Canada
- Volunteers
- 66 people
- Sponsor
- The Hospital for Sick Children
Blood Disease, Hemophilia A
Epidemiology and Immunology of Hemophilia A Inhibitors
To determine the risk factors associated with inhibitor formation in hemophilia A and to study the mechanism of tolerance in the murine hemophilia A model.
- Trial name
- NCT00005518
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hemophilia A
Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A
The purpose of this study is to evaluate the rate of response when administering rituximab to suppress or eliminate the anti-body in a patient's blood that inhibits the effectiveness of their factor replacement product compared…
- Trial name
- NCT00306670
- Testing
- Rituxan, prednisone
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Georgetown University
Hemophilia B
Safety of a New Type of Treatment Called Gene Transfer for the Treatment of Severe Hemophilia B
In this study a modified virus called adeno-associated virus (AAV) will be used to transfer a normal gene for human clotting factor IX into patients with severe hemophilia B (AAV human Factor IX vector).
- Trial name
- NCT00076557
- Testing
- Adeno-Associated Viral with Human Factor IX
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Avigen
Hemophilia A
Emotions in the Communication and Relationship Styles of Parents With Hemophilic Children.
Severe hemophilia is a rare, inherited, X-linked disorder. Currently, standard therapy involves ev infusion of drugs from a very young age.
- Trial name
- NCT05754619
- Where
- Italy
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Hemophilia a, Hemophilia B
The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B
The purpose of the study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of prophylactic SerpinPC administered subcutaneously (SC) to participants with severe hemophilia A (HemA) (with or without…
- Trial name
- PRESent-2 (NCT05789524)
- Testing
- SerpinPC
- Where
- 59 sites in United States, Armenia and 13 more
- Volunteers
- 60 people
- Sponsor
- ApcinteX Ltd
Hemophilia A
Hemophilia Inhibitor Previously Untreated Patient Study
Hemophilia A is a congenital bleeding disorder caused by deficiency of factor VIII (FVIII) and is treated by replacement therapy with FVIII concentrate.
- Trial name
- HIPS (NCT01652027)
- Testing
- FVIII concentrate
- Where
- 17 sites in United States, Austria and 3 more
- Volunteers
- 25 people
- Sponsor
- The University of Texas Health Science Center, Houston
Hemophilia A
Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies
This US study will assess hemophilia A patient characteristics, health history and reasons for switching or not switching from both patient/caregiver and physician perspectives.
- Trial name
- PARkER (NCT03405337)
- Testing
- FVIII products, Conventional FVIII replacement therapies
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Bayer
Hemophilia A Without Inhibitor
Multidimensional Assessment of Chronic Pain in Severe Haemophilia A
Introduction: Haemophilia is a congenital coagulopathy characterised by haemarthrosis, mainly in the knees, ankles and elbows. Prophylactic treatment is the most effective therapeutic option for preventing or minimising these…
- Trial name
- NCT07096349
- Where
- Spain
- Volunteers
- 109 people
- Sponsor
- Investigación en Hemofilia y Fisioterapia
Prophylaxis, Hemophilia A
Comparison of Prophylaxis and On-demand Treatment in Children With Moderate to Severe Hemophilia A
Comparison of prophylaxis and on-demand treatment in children with moderate to severe hemophilia A. This study determines to compare the efficacy of prophylaxis and on-demand treatment in moderate to severe hemophilia A children…
- Trial name
- NCT02362581
- Testing
- prophylaxis treatment, on demand treatment
- Where
- Thailand
- Volunteers
- 15 people
- Sponsor
- Chulalongkorn University
Hemophilia A
A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
Primary objective: To assess the pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc fusion protein for Injection at two dose levels in patients with hemophilia A.
- Trial name
- NCT03747653
- Testing
- ADVATE, FRSW107
- Where
- 5 sites in China
- Volunteers
- 12 people
- Sponsor
- Kaifeng Pharmaceutical (Group) Co., Ltd.
Bleeding Disorder
Screening for Bleeding Disorders in Children
The investigators try to improve the screening of bleeding disorders in children by identifying symptoms, laboratory abnormalities and clinical scores discriminating patients congenital bleeding disorders in order to create a…
- Trial name
- NCT05214300
- Where
- France
- Volunteers
- 96 people
- Sponsor
- University Hospital, Montpellier
Hemophilia, Chronic Synovitis
Intra-Articular Bevacizumab for Preventing Recurrent Hemarthrosis in Hemophilia With Chronic Synovitis
Hemophilia is an inherited bleeding disorder characterized by deficiency of clotting factors, leading to increased bleeding tendencies.
- Trial name
- NCT07187661
- Testing
- Intra-articular Bevacizumab
- Where
- 2 sites in Pakistan
- Volunteers
- 18 people
- Sponsor
- Khyber Medical University Peshawar
Healthy
A Phase I Study of Monoclonal Antibody TB-402 in Healthy Male Volunteers
Dose escalation study to assess the safety and tolerability of TB-402, a monoclonal antibody directed against FVIII, versus placebo in healthy male volunteers.
- Trial name
- NCT00612196
- Testing
- TB-402
- Where
- Denmark
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- ThromboGenics
Hemophilia A
Study of a Gene Therapy Treatment for Hemophilia A
The purpose of this study is to evaluate the efficacy of SPK-8011 in preventing bleed episodes compared with FVIII prophylaxis in participants with hemophilia A without FVIII inhibitors on routine FVIII prophylaxis.
- Trial name
- KEYSTONE 1 (NCT06297486)
- Testing
- SPK-8011
- Where
- 27 sites in United States
- Sponsor
- Spark Therapeutics, Inc.
Hemophilia A
Individually Tailored Prophylaxis in Patients With Severe Hemophilia A
Patients with severe haemophilia A lack clotting factor FVIII and suffer from spontaneous and traumatic bleeds. In the absence of treatment, frequent bleeds in joints lead to severe joint destruction.
- Trial name
- OPTIPHASE (NCT00995046)
- Testing
- FVIII
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Hospices Civils de Lyon